Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GPCR NASDAQ:OZEM NYSEARCA:THNR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$42.91-0.4%$43.22$15.80▼$94.90$3.06B-1.35708,805 shs714,684 shsOZEMRoundhill GLP-1 & Weight Loss ETF$30.48-1.0%$31.17$23.22▼$37.15$50.60M0.4325,898 shs12,998 shsTHNRAmplify Weight Loss Drug & Treatment ETF$24.26-0.5%$24.53$21.70▼$27.28$4.12M0.42,019 shs374 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics+0.33%+14.03%+11.32%-23.29%+98.66%OZEMRoundhill GLP-1 & Weight Loss ETF+0.72%+3.36%-0.23%-2.41%+13.45%THNRAmplify Weight Loss Drug & Treatment ETF-0.16%+1.84%-0.20%-1.10%+3.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$42.91-0.4%$43.22$15.80▼$94.90$3.06B-1.35708,805 shs714,684 shsOZEMRoundhill GLP-1 & Weight Loss ETF$30.48-1.0%$31.17$23.22▼$37.15$50.60M0.4325,898 shs12,998 shsTHNRAmplify Weight Loss Drug & Treatment ETF$24.26-0.5%$24.53$21.70▼$27.28$4.12M0.42,019 shs374 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics+0.33%+14.03%+11.32%-23.29%+98.66%OZEMRoundhill GLP-1 & Weight Loss ETF+0.72%+3.36%-0.23%-2.41%+13.45%THNRAmplify Weight Loss Drug & Treatment ETF-0.16%+1.84%-0.20%-1.10%+3.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPCRStructure Therapeutics 2.89Moderate Buy$106.75148.60% UpsideOZEMRoundhill GLP-1 & Weight Loss ETF 2.62Moderate Buy$30.580.33% UpsideTHNRAmplify Weight Loss Drug & Treatment ETF 2.60Moderate Buy$24.16N/ACurrent Analyst Ratings BreakdownLatest OZEM, THNR, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026GPCRStructure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $70.004/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$101.004/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$101.004/21/2026GPCRStructure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026GPCRStructure Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/17/2026GPCRStructure Therapeutics BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$145.003/16/2026GPCRStructure Therapeutics William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform3/16/2026GPCRStructure Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform3/16/2026GPCRStructure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$114.00 ➝ $100.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/AOZEMRoundhill GLP-1 & Weight Loss ETFN/AN/AN/AN/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPCRStructure Therapeutics-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)OZEMRoundhill GLP-1 & Weight Loss ETFN/AN/A22.34N/AN/AN/AN/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AN/A24.31N/AN/AN/AN/AN/AN/ALatest OZEM, THNR, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39-$0.35+$0.04-$0.35$11.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGPCRStructure TherapeuticsN/AN/AN/AN/AN/AOZEMRoundhill GLP-1 & Weight Loss ETF$0.050.16%N/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETF$0.220.91%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPCRStructure TherapeuticsN/A26.1626.16OZEMRoundhill GLP-1 & Weight Loss ETFN/AN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPCRStructure Therapeutics91.78%OZEMRoundhill GLP-1 & Weight Loss ETFN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/AInsider OwnershipCompanyInsider OwnershipGPCRStructure Therapeutics5.50%OZEMRoundhill GLP-1 & Weight Loss ETFN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPCRStructure Therapeutics13671.07 million67.17 millionOptionableOZEMRoundhill GLP-1 & Weight Loss ETFN/A1.66 millionN/AN/ATHNRAmplify Weight Loss Drug & Treatment ETFN/A170,000N/AN/AOZEM, THNR, and GPCR HeadlinesRecent News About These CompaniesHealthcare ETFs: From Broad Exposure to Big BreakthroughsJune 11, 2026 | etftrends.comEInside the GLP-1 Boom: ETF Picks for the Obesity Drug MarketJune 10, 2026 | zacks.comAmplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Trading Up 0.4% - Time to Buy?June 10, 2026 | americanbankingnews.comLLY Clears Major Obesity Trial: Get Exposure in THNRMay 21, 2026 | etftrends.comEGLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to GainMay 19, 2026 | zacks.com3 Ways to Invest in the Growing GLP-1 Weight Loss Market (THNR)...April 17, 2026 | marketbeat.comWeight Loss ETF THNR Reweights Its Index: What's Up & DownMarch 25, 2026 | etftrends.comEAmplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest UpdateMarch 13, 2026 | defenseworld.netDETFs tied to HIMS gain attention as the telehealth stock spikesMarch 9, 2026 | msn.comHealthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales OutlookFebruary 4, 2026 | zacks.comNew Year, New Strategy: Navigating Weight Loss ETFsJanuary 12, 2026 | etftrends.comEHims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFsSeptember 18, 2025 | benzinga.comWeight Loss Drug ETF (THNR) Hits New 52-Week HighJune 2, 2025 | zacks.comNew Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFsJanuary 17, 2025 | etftrends.comEDisruptive Theme of the Week – Breakthroughs in MedicineNovember 21, 2024 | etftrends.comEAmplify ETFs Hits $10 Billion in Assets Amid New ETF LaunchesOctober 29, 2024 | etftrends.comETap the Weight-Loss Drug Market With These ETFsSeptember 18, 2024 | zacks.comDisruptive Theme of the Week: Playing DefenseAugust 14, 2024 | etftrends.comEETFs in Focus as Competition Heats Up in Weight Loss Drug SegmentJuly 22, 2024 | zacks.comTop Themes in the First Half of 2024: Crypto, Chips, Ships & SilverJuly 2, 2024 | etftrends.comEWhy Investors Haven't Feasted on Two New Weight-Loss ETFsJune 24, 2024 | investopedia.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?By Jessica Mitacek | May 28, 2026OZEM, THNR, and GPCR Company DescriptionsStructure Therapeutics NASDAQ:GPCR$42.91 -0.16 (-0.37%) Closing price 04:00 PM EasternExtended Trading$42.60 -0.31 (-0.72%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Roundhill GLP-1 & Weight Loss ETF NASDAQ:OZEM$30.48 -0.30 (-0.97%) As of 03:59 PM EasternThe Roundhill GLP-1 & Weight Loss ETF (OZEM) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies from around the world involved in pharmaceutical drugs and supplements used for weight management. OZEM was launched on May 21, 2024 and is issued by Roundhill.Amplify Weight Loss Drug & Treatment ETF NYSEARCA:THNR$24.26 -0.12 (-0.49%) As of 04:10 PM EasternThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
